Hospital-acquired bacterial pneumonia

Also known as: Nosocomial Pneumonia (NP) / Nosocomial penumonia / Hospital Acquired Pneumonia (HAP) / Nosocomial pneumonia / Hospital acquired pneumonia / Pneumonia / Pneumonia NOS / Pulmonitis

DrugDrug NameDrug Description
DB00479AmikacinAmikacin is a semi-synthetic aminoglycoside antibiotic that is derived from kanamycin A [FDA label]. Amikacin is synthesized by acylation with the l-(-)-γ-amino-α-hydroxybutyryl side chain at the C-1 amino group of the deoxystreptamine moiety of kanamycin A [A39531]. Amikacin's unique property is that it exerts activity against more resistant gram-negative bacilli such as Acinetobacter baumanii and Pseudomonas aeruginosa. Amikacin also exerts excellent activity against most aerobic gram-negative bacilli from the Enterobacteriaceae family, including Nocardia and some Mycobacterium (M. avium-intracellulare, M. chelonae, and M. fortuitum)[L4680]. M. avium-intracellulare (MAC) is a type of nontuberculous mycobacteria (NTM) found in water and soil. Symptoms of this disease include a persistent cough, fatigue, weight loss, night sweats, and shortness of breath and the coughing up of blood [L4680]. Several forms of amikacin are used currently, including an intravenous (IV) or intramuscular (IM) injection [F1949]. In September 2018, a liposomal inhalation suspension of this drug was approved by the FDA for the treatment of lung disease caused by Mycobacterium avium complex (MAC) bacteria in a small population of patients with the disease who do not respond to traditional treatment [L4680],[L4681].
DB04918CeftobiproleCeftobiprole is an experimental cephalosporin antibiotic with activity against methicillin-resistant Staphylococcus aureus. It was discovered by Basilea Pharmaceutica and is being developed by Johnson & Johnson Pharmaceutical Research and Development. Ceftobiprole is the first cephalosporin to demonstrate clinical efficacy in patients with infections due to methicillin-resistant staphylococci and, if approved by regulatory authorities, is expected to be a useful addition to the armamentarium of agents for the treatment of complicated skin infections and pneumonia.
DB00537CiprofloxacinCiprofloxacin is a broad-spectrum antimicrobial carboxyfluoroquinoline.The bactericidal action of ciprofloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, strand supercoiling repair, and recombination.
DB01137LevofloxacinA synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
DB00601LinezolidLinezolid is a synthetic antibiotic, the first of the oxazolidinone class, used for the treatment of infections caused by multi-resistant bacteria including streptococcus and methicillin-resistant Staphylococcus aureus (MRSA). The drug works by inhibiting the initiation of bacterial protein synthesis.
DB09324SulbactamSulbactam is a β-lactamase inhibitor given in combination with β-lactam antibiotics to inhibit β-lactamase, an enzyme produced by bacteria that destroys antibiotic activity.
DB06402TelavancinTelavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and subcutaneous tissue infections among others.
DrugDrug NameTargetType
DB00479Amikacin30S ribosomal protein S12target
DB04918CeftobiproleMecAtarget
DB04918CeftobiprolePenicillin-binding protein 2xtarget
DB04918CeftobiprolePeptidoglycan synthase FtsItarget
DB00537CiprofloxacinDNA gyrase subunit Atarget
DB00537CiprofloxacinDNA topoisomerase 4 subunit Atarget
DB00537CiprofloxacinDNA topoisomerase 2-alphatarget
DB00537CiprofloxacinCytochrome P450 1A2enzyme
DB00537CiprofloxacinCytochrome P450 3A4enzyme
DB00537CiprofloxacinCytochrome P450 3A5enzyme
DB00537CiprofloxacinCytochrome P450 3A7enzyme
DB00537CiprofloxacinMultidrug resistance protein 1transporter
DB00537CiprofloxacinPotassium voltage-gated channel subfamily H member 2target
DB00537CiprofloxacinDNA gyrase subunit Atarget
DB00537CiprofloxacinDNA topoisomerase 4 subunit Atarget
DB00537CiprofloxacinDNA topoisomerase 4 subunit Btarget
DB00537CiprofloxacinDNA gyrase subunit Atarget
DB00537CiprofloxacinMultidrug resistance protein MdtKtarget
DB00537CiprofloxacinGyrase Atarget
DB00537CiprofloxacinDNA gyrase subunit Atarget
DB00537CiprofloxacinMultidrug and toxin extrusion protein 1transporter
DB00537CiprofloxacinMultidrug and toxin extrusion protein 2transporter
DB01137LevofloxacinDNA gyrase subunit Atarget
DB01137LevofloxacinDNA topoisomerase 4 subunit Atarget
DB01137LevofloxacinDNA topoisomerase 2-alphatarget
DB01137LevofloxacinCytochrome P450 1A2enzyme
DB01137LevofloxacinSolute carrier family 22 member 2transporter
DB01137LevofloxacinMultidrug resistance protein 1transporter
DB01137LevofloxacinSolute carrier family 22 member 4transporter
DB01137LevofloxacinSolute carrier family 22 member 6transporter
DB01137LevofloxacinCytochrome P450 3A4enzyme
DB01137LevofloxacinMultidrug and toxin extrusion protein 1transporter
DB01137LevofloxacinMultidrug and toxin extrusion protein 2transporter
DB00601Linezolid23S rRNAtarget
DB00601LinezolidAmine oxidase [flavin-containing] Aenzyme
DB00601LinezolidAmine oxidase [flavin-containing] Benzyme
DB09324SulbactamBeta-lactamasetarget
DrugDrug NamePhaseStatusCount
DB08816Ticagrelor1Completed1
DB12765Methyl isocyanate2 / 3Unknown Status1
DB09050Ceftolozane3Completed1
DB00803Colistin3Completed1
DB00803Colistin3Recruiting1
DB13900Equine Botulinum Neurotoxin A Immune FAB23Active Not Recruiting1
DB13903Equine Botulinum Neurotoxin B Immune FAB23Active Not Recruiting1
DB13898Equine Botulinum Neurotoxin C Immune FAB23Active Not Recruiting1
DB13902Equine Botulinum Neurotoxin D Immune FAB23Active Not Recruiting1
DB13897Equine Botulinum Neurotoxin E Immune FAB23Active Not Recruiting1
DB13901Equine Botulinum Neurotoxin F Immune FAB23Active Not Recruiting1
DB13899Equine Botulinum Neurotoxin G Immune FAB23Active Not Recruiting1
DB01598Imipenem3Completed1
DB01598Imipenem3Recruiting1
DB01137Levofloxacin3Completed1
DB00601Linezolid3Completed1
DB00601Linezolid3Recruiting1
DB00760Meropenem3Completed3
DB00319Piperacillin3Withdrawn1
DB01045Rifampicin3Completed1
DB09324Sulbactam3Recruiting1
DB01606Tazobactam3Completed1
DB01606Tazobactam3Withdrawn1
DB00878Chlorhexidine4Completed1
DB00601Linezolid4Completed1
DB13831Potassium permanganate4Completed1
DB00512Vancomycin4Completed1
DB00802AlfentanilNot AvailableRecruiting1
DB00479AmikacinNot AvailableRecruiting1
DB00513Aminocaproic AcidNot AvailableRecruiting1
DB00559BosentanNot AvailableRecruiting1
DB01413CefepimeNot AvailableRecruiting1
DB00369CidofovirNot AvailableRecruiting1
DB00537CiprofloxacinNot AvailableRecruiting1
DB00363ClozapineNot AvailableRecruiting1
DB00828FosfomycinNot AvailableRecruiting1
DB00502HaloperidolNot AvailableRecruiting1
DB00598LabetalolNot AvailableRecruiting1
DB08815LurasidoneNot AvailableRecruiting1
DB00959MethylprednisoloneNot AvailableRecruiting1
DB01618MolindoneNot AvailableRecruiting1
DB00607NafcillinNot AvailableRecruiting1
DB01115NifedipineNot AvailableRecruiting1
DB00497OxycodoneNot AvailableRecruiting1
DB00312PentobarbitalNot AvailableRecruiting1
DB00728RocuroniumNot AvailableRecruiting1
DB00658SevelamerNot AvailableRecruiting1
DB00421SpironolactoneNot AvailableRecruiting1
DB00684TobramycinNot AvailableRecruiting1
DB00302Tranexamic acidNot AvailableRecruiting1
DB00512VancomycinNot AvailableRecruiting1
DB01339VecuroniumNot AvailableRecruiting1
DB00682WarfarinNot AvailableRecruiting1
DB00246ZiprasidoneNot AvailableRecruiting1
DB00425ZolpidemNot AvailableRecruiting1